India Pharma Outlook Team | Thursday, 19 November 2026
AstraZeneca Pharma India is exploring new opportunities in India's cancer care landscape through a proposed collaboration with Reliance Industries subsidiary Strand Life Sciences.
The two companies have signed a Letter of Intent (LoI) to explore potential healthcare partnerships, bringing pharmaceutical research and genomics expertise under one framework.
The move highlights the growing importance of precision medicine, where genomic insights can help guide disease diagnosis and treatment decisions. While the agreement marks an initial step, it could create opportunities to connect pharmaceutical innovation with genomics-led healthcare solutions in India.
The proposed collaboration combines two different areas of healthcare expertise. AstraZeneca Pharma India focuses on pharmaceutical innovation, with a strong presence in oncology, biopharmaceuticals, and rare diseases. Strand Life Sciences, a Reliance Industries subsidiary, specializes in genomics research and diagnostics.
Their complementary capabilities could create opportunities to explore more personalized approaches to disease management.
Commenting on the development, Praveen Rao Akkinepally, Country President and Managing Director of AstraZeneca Pharma India, highlighted the company's science-led portfolio and its efforts across oncology, biopharmaceuticals and rare diseases.
The intersection of these capabilities holds particular relevance for precision medicine, which increasingly connects genomic information with treatment approaches.
Also Read: India's 30% Anti-Cancer Drug Margin Cap: What It Means for Pharma
The proposed collaboration could open new avenues for India's cancer care ecosystem by bringing drug research and genomic diagnostics closer together.
Potential areas of opportunity include:
However, the companies have not announced specific projects, investment commitments, commercial arrangements, or implementation timelines. The agreement therefore represents an opportunity to explore shared interests rather than a confirmed oncology initiative. Its eventual contribution to India's cancer care landscape will depend on the projects and research priorities both companies pursue.